Seroatlas · Human Serome Atlas

NOP9

Nucleolar protein 9

Also known as: C14orf21, NOP9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86U38
Gene: NOP9
Ensembl: ENSG00000196943
Chromosome: 14
Canonical length: 636 aa
Protein class: Plasma proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nucleoli,Cytosol

OverviewNCBI Gene

Enables RNA binding activity. Predicted to be involved in ribosome biogenesis. Predicted to be part of 90S preribosome and preribosome, small subunit precursor. Predicted to be active in nucleolus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

636 residues, UniProt reviewed canonical sequence.

>Q86U38|NOP9
     1  MGQGPRSPHK VGRRFPAGGK RGRGAKGSGR PLPGRKRQPW PPPDGRSEPA PDSHPHLSPE
    61  ALGYFRRALS ALKEAPETGE ERDLMVHNIM KEVETQALAL STNRTGSEML QELLGFSPLK
   121  PLCRVWAALR SNLRTVACHR CGVHVLQSAL LQLPRLLGSA AEEEEEEEED GKDGPTETLE
   181  ELVLGLAAEV CDDFLVYCGD THGSFVVRTL LQVLGGTILE SERARPRGSQ SSEAQKTPAQ
   241  ECKPADFEVP ETFLNRLQDL SSSFLKDIAV FITDKISSFC LQVALQVLHR KLPQFCAHLC
   301  NAVIGYLSTR GSSVDGSPLL LFLRDQTSSR LLEQVLLVLE PPRLQSLFEE HLQGQLQTLA
   361  AHPIANFPLQ RLLDAVTTPE LLSPVFEELS PVLEAVLAQG HPGVVIALVG ACRRVGAYQA
   421  KVLQLLLEAF HCAEPSSRQV ACVPLFATLM AYEVYYGLTE EEGAVPAEHQ VAMAAARALG
   481  DVTVLGSLLL QHLLHFSTPG LVLRSLGALT GPQLLSLAQS PAGSHVLDAI LTSPSVTRKL
   541  RRRVLQNLKG QYVALACSRH GSRVLDAIWS GAALRARKEI AAELGEQNQE LIRDPFGHHV
   601  ARNVALTTFL KRREAWEQQQ GAVAKRRRAL NSILED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NOP9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 26 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 26 nTPM
spleen: 18 nTPM
esophagus: 16 nTPM
liver: 14 nTPM
adrenal gland: 13 nTPM
heart muscle: 12 nTPM

Single-cell type

retinal pigment epithelial cells: 4.3 nCPM
cholangiocytes: 3.9 nCPM
early spermatids: 2.7 nCPM
esophageal apical cells: 2.5 nCPM
erythrocyte progenitors: 2.3 nCPM
late primary spermatocytes: 2.1 nCPM

Immune cell

non-classical monocyte: 1.2 nTPM
intermediate monocyte: 0.7 nTPM
classical monocyte: 0.6 nTPM
eosinophil: 0.5 nTPM
MAIT T-cell: 0.5 nTPM
myeloid DC: 0.5 nTPM

Brain region

spinal cord: 12 nTPM
thalamus: 12 nTPM
medulla oblongata: 12 nTPM
basal ganglia: 11 nTPM
midbrain: 11 nTPM
pons: 11 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.03
gnomAD pLI: 0
gnomAD missense Z: 0.45
DepMap mean gene effect: -0.83
DepMap dependency class: common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

RNA binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

Pumilio RNA-binding repeat
Armadillo-like helical
Armadillo-type fold
Nucleolar protein 9
NOP9-like PUF repeat domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NOP9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

RBM19

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NOP9 as an antibody target. Whether an autoantibody or antibody against NOP9 could matter depends on whether native NOP9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NOP9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NOP9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...